Sutent
(Sunitinib Malate)Phase 2
Sutent is one of 14 small molecule programs targeting Thymic Carcinoma. It is currently in Phase 2.
2
Indications
8
Total Trials
6
Active Trials
13
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Thymic Carcinoma
#DrugCompanyPhaseTrials
1Gleevec
NovartisApproved
Beleodaq
AAcrotech Biopharma Inc.
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Vepesid
AAvyxa
Phase 3
Sutent
PfizerPhase 2
Keytruda
Merck & Co.Phase 2
Lenvima
EisaiPhase 2
Taxol
TevaPhase 2
Trodelvy
GileadPhase 2
Paraplatin
AAvyxa
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ciliary Body and Choroid Melanoma, Medium/Large Size1 trial
A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT02068586·210 enrolled
Thymic Carcinoma1 trial
3 more indications
Malignant Neoplasms of Urinary Tract1 trial
Stage IIIB Lung Non-Small Cell Cancer AJCC v71 trial
Regulatory
FDA Approval Timeline[4]
Jan 26, 2006
SUTENT
NDA NDA021938
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sunitinib Malate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]